Hyperliquid Strategies expanded its equity financing facility with Chardan Capital Markets from $1 billion to $2.5 billion on Sept. 1, according to a new U.S. Securities and Exchange Commission filing.
Summary
- Hyperliquid Strategies expanded its Chardan equity facility from $1 billion to $2.5 billion in capacity.
- The facility permits periodic share sales but does not guarantee the company raises $2.5 billion.
- Proceeds may fund general corporate purposes, including potential HYPE purchases, subject to discretion and conditions.
- A 42,641,847-share exchange cap applies to certain below-$12.02 sales after the first $1 billion raised.
- PURR closed at $11.36 on September 1, falling approximately 7.3% during the regular trading session.
The Nasdaq-listed company can raise funds over time by selling newly issued PURR shares to Chardan. Hyperliquid Strategies previously said proceeds from the facility could support general corporate purposes, including potential purchases of HYPE, the native token of the Hyperliquid network.
The $2.5 billion commitment represents the facility’s maximum aggregate capacity. It does not mean the company has received that amount, completed an offering of that size or committed the proceeds to buying HYPE.
Actual proceeds will depend on the number of shares sold and the prices at which transactions occur. Each issuance would also increase PURR’s outstanding share count, creating potential dilution for existing investors.
Hyperliquid Strategies adds $1.5 billion in capacity
Hyperliquid Strategies and Chardan signed the amendment to their ChEF purchase agreement on Sept. 1. The original agreement dates to Oct. 22, 2025.
The amendment raises the total commitment by $1.5 billion. Chardan can purchase newly issued common shares from Hyperliquid Strategies after the company submits qualifying purchase notices under the agreement.
Hyperliquid Strategies controls the timing and amount of individual sales. Its SEC disclosures state that financing decisions will depend on market conditions, PURR’s trading price and management’s assessment of how the proceeds should be deployed.
The arrangement differs from a traditional loan. Selling shares does not create principal repayments or interest expenses. However, the company exchanges equity for cash, reducing the percentage ownership represented by each existing share.
The facility also does not guarantee that Chardan will purchase $2.5 billion in stock. Transactions remain subject to the agreement’s terms, conditions and limitations. The amount ultimately raised could be lower than the maximum commitment.
Potential HYPE purchases remain optional
Hyperliquid Strategies said in its prospectus that proceeds from equity-facility sales were planned for general corporate purposes, including potential HYPE purchases.
That language gives management broad discretion. It does not establish a minimum HYPE allocation, purchasing deadline or fixed token target. The company could also direct proceeds toward operating expenses, transaction costs or other corporate requirements.
The Sept. 1 Form 8-K does not report a new HYPE acquisition. It also does not disclose whether Hyperliquid Strategies has completed share sales using the additional $1.5 billion of capacity.
Hyperliquid Strategies reported holding 29.3 million HYPE as of Aug. 19. Since completing its business combination in December 2025, the company had spent $773.4 million to acquire approximately 16.5 million tokens at an average price of $46.77, as crypto.news reported.
The company also reported $149.9 million in cash at the end of June and said it carried no debt. Its HYPE position had more than doubled from the roughly 12.6 million tokens associated with the company’s creation.
In related coverage, the transaction that formed Hyperliquid Strategies included $305 million in cash alongside the initial HYPE contribution. The company has since used equity financing as a central part of its token accumulation strategy.
Nasdaq rules limit lower-priced issuances
The amendment introduces an exchange cap that becomes relevant after aggregate share sales through the facility reach $1 billion.
After that threshold, Hyperliquid Strategies generally cannot sell more than 42,641,847 shares at prices below $12.02. The limit equals 19.99% of the common shares outstanding immediately before the amendment was executed.
The company can exceed the cap if shareholders approve additional issuances under Nasdaq rules. The restriction may also cease to apply if shareholder approval is not required under an available Nasdaq provision.
At $12.02 per share, 42,641,847 shares would represent approximately $512.5 million in gross proceeds. This calculation excludes fees and assumes every share is sold at the stated price.
The relationship between the share cap and the expanded commitment could restrict access to the full facility when PURR trades below $12.02. Raising the entire $2.5 billion may require higher sale prices, shareholder approval or an applicable Nasdaq exception.
The effect on existing investors will depend on the timing and size of each issuance. Selling shares at lower prices requires the company to issue more stock to raise the same amount of cash, increasing dilution.
PURR closes below the amendment’s threshold
PURR closed at $11.36 on Sept. 1, down approximately 7.3% during regular trading. The stock opened at $11.76 and traded between $11.03 and $12.31. Volume reached about 24.3 million shares.
The closing price placed PURR below the amendment’s $12.02 reference level. However, the market price does not activate the exchange cap by itself. The restriction concerns completed below-threshold sales after cumulative facility purchases reach $1 billion.
